Company intelligence / Profile preview

Encompass Vascular

San Jose, California, United Statespitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

The F2 filter demonstrated strong preclinical performance, blocking up to 94% more emboli than the leading competitor in vitro. First-in-human use in Europe showed 100% procedural success with no adverse events. FDA granted conditional IDE approval for US pilot study as of September 2023.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Collaborations with international medical centers for early clinical studies (e.g., Israeli-Georgian Medical Research Clinic, Columbia University physicians)

Beyond the preview

Go deeper on Encompass Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Encompass Vascular.

Explore the full profile